HOMCY CHARLES J — SEC Form 4 filings
SEC reporting owner CIK 1192591. 13 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-02-21 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 300,000 shares, $13,912,443 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
- Largest priced transaction: sale of 191,662 shares @ $45.87 ($8,791,593) in BridgeBio Pharma, Inc., filed 2025-08-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | Director | 7 | — | 3 legs · 300,000 sh · $13,912,443 | 10 |
| Maze Therapeutics, Inc. (MAZE) | Director | 6 | — | — | 20 |
Form 4 filings — HOMCY CHARLES J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | BridgeBio Pharma, Inc. (BBIO) | Tax withholding (F): 788 @ $66.27 | EDGAR |
| 2026-06-10 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Maze Therapeutics, Inc. (MAZE) | Gift (G): 7,422 @ $0 | EDGAR |
| 2025-11-21 | 4 | Maze Therapeutics, Inc. (MAZE) | Other (J): 1,489 @ $0 | EDGAR |
| 2025-10-27 | 4 | Maze Therapeutics, Inc. (MAZE) | Gift (G): 28,423 @ $0 | EDGAR |
| 2025-09-24 | 4 | Maze Therapeutics, Inc. (MAZE) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | BridgeBio Pharma, Inc. (BBIO) | Sale (S): 191,662 @ $45.87 · Sale (S): 58,338 @ $46.64 · Sale (S): 50,000 @ $48 | EDGAR |
| 2025-06-30 | 4 | BridgeBio Pharma, Inc. (BBIO) | Gift (G): 20,000 @ $0 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Maze Therapeutics, Inc. (MAZE) | Conversion (C): 8,807 · Conversion (C): 20,717 · Conversion (C): 7,422 · Conversion (C): 72,727 (derivative) · Conversion (C): 169,405 (derivative) · Conversion (C): 71,564 (derivative) · +9 more | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 3,760 · Tax withholding (F): 1,509 @ $37.21 · Option exercise (M): 3,760 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1192591 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →